-

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma
Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic…
-

2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women?
The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: “Educate, Advocate, Act,” aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to…
-

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations
Part 1: Cirrhosis Extracellular Vesicles Secreted by Injured Hepatocytes Drive Cirrhosis-Associated Muscle Wasting Through the mtDNA-cGAS-STING Axis (Oral Presentation) • Authors: Fan Xiaoli, Peng Yunke, Li Bo • Corresponding Authors:…
-

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations
Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment…
-

Combination Therapy for Advanced Gastric and Esophageal Cancers: Results from the OASIS Trial
Study Design and Participants The trial enrolled 48 participants, including 45 patients with GAC and 3 with ESCC. The therapy involved administering nivolumab 360 mg every three weeks alongside anlotinib…
-

AASLD 2024丨Dr. Qing Xie ‘s Team: Digital Precision Screening and Risk Stratification Improve Early Detection of Liver Cancer in China
Project Overview and Methods The study analyzed data from Ruijin Hospital and Lishui People’s Hospital, two participants in the “Ruiganhu” project. Between May 2023 and March 2024, a total of…
-

CCHIO 2024丨Dr. Qingbo Wang: Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer
At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the Infectious Tumors Subcommittee session, Dr. Qingbo Wang from The Second Hospital of Nanjing presented a report titled “Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer.” The presentation explored the epidemiology, diagnostic challenges, and treatment strategies for patients with coexisting tuberculosis (TB) and lung cancer.
-

CCHIO 2024丨Dr. Xiaohua Wu: Enhancing Preoperative Evaluation Strategies for Advanced Ovarian Cancer Patients
The historic city of Xi’an became a gathering place for top global oncologists as the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Socitey (AOS) took place from November 14 to 17. This event symbolized a significant integration of the global oncology community. During the gynecologic oncology session at CCHIO, Dr.…